do some people not respond to semaglutide Weight loss drug helps patients who bariatric surgery, research finds Many people start and stop

Learn what to expect at 1, 3, 6, and 12 months with expert medical insight.

Ro and LifeMD are telehealth platforms offering GLP-1 medications for weight management and diabetes, but they differ in clinical assessment depth, medication options, and pricing models

A runny nose during GLP-1 therapy raises questions about whether the medication itself causes nasal symptoms or if other factors are at play

As Donovan notes, GLP-1 medication is not cheap if purchased by a private individual, estimating that only one in five adults has insurance that would cover anti-obesity medication

The study also reported a 42% lower risk of psychiatric hospitalizations and work absences during periods when patients were taking semaglutide compared with periods when they were not.

AstraZeneca - Building a strong obesity and metabolic disease pipeline Amgen - MariTide showing promising obesity treatment potential Roche - Expanding through strategic acquisitions and obesity-focused programs Pfizer - Continuing development efforts in oral obesity medicines Structure Therapeutics - Advancing next-generation oral GLP-1 candidates Viking Therapeutics - Emerging as a major obesity treatment contender Altimmune - Developing innovative metabolic disease therapies Boehringer Ingelheim - Investing in future cardiometabolic opportunities Why is everyone chasing GLP-1